Investment
Features
FeesSafety
Academy
More
Pluang+

Audiencerate names Riccardo Fabbri CTO to lead AI-driven growth for Italian SMEs and global media agencies

Others
21 May 2026
Not Specified
View Source
Bullish
Audiencerate names Riccardo Fabbri CTO to lead AI-driven growth for Italian SMEs and global media agencies

Audiencerate Ltd appointed Riccardo Fabbri as Chief Technology Officer to spearhead AI-driven platform development for Italian SMEs and global media agencies. Fabbri brings over 20 years of experience in software and cloud architecture, having co-founded Nohup and led its acquisition by Havas Group. Under his leadership, Audiencerate will enhance its platforms using first- and third-party data integration with AI and machine learning, improving predictive modeling and budget optimization for SMEs and advanced audience targeting for agencies. This move aims to strengthen Audiencerate's position as a key data provider within Google and Microsoft ecosystems while addressing privacy and regulatory compliance.

More News

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...

Market News
Bullish
2 hours ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
4 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
4 hours ago
Solana's non-vote transactions hit 8.92B in Q3 2026, up 104% from Q4 2025, setting new weekly and monthly records.

Solana's non-vote transactions hit 8.92B in Q3 2026, up 104% from Q4 2025, setting new weekly and monthly records.

Solana recorded 8.92 billion non-vote transactions from July to September 2026, marking a 104% increase compared to the fourth quarter of 2025. These transactions exclude validator votes and include activities like transfers, trading, and decentraliz...

Protocol Fundamentals
Bullish
4 hours ago
Jio Platforms' IPO anchor book oversubscribed 30x with $26.3B bids from top global investors

Jio Platforms' IPO anchor book oversubscribed 30x with $26.3B bids from top global investors

Jio Platforms, backed by Meta and Google, has seen its IPO anchor book oversubscribed over 30 times, attracting $26.3 billion in bids for an $854 million portion. The company aims to raise up to $3.2 billion in India's largest-ever IPO by rupee value...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App